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Atherosclerosis is a complex multifocal arterial disease involving interactions of multiple genetic and environmental factors.
Advances in techniques of molecular genetics have revealed that genetic ground signiﬁcantly inﬂuences susceptibility to
atherosclerotic vascular diseases. Besides further investigations of monogenetic diseases, candidate genes, genetic polymorphisms,
and susceptibility loci associated with atherosclerotic diseases have been identiﬁed in recent years, and their number is rapidly
increasing. This paper discusses main genetic investigations ﬁelds associated with human atherosclerotic vascular diseases. The
paper concludes with a discussion of the directions and implications of future genetic research in arteriosclerosis with an emphasis
on prospective prediction from an early age of individuals who are predisposed to develop premature atherosclerosis as well as to
facilitate the discovery of novel drug targets.
1.Introduction
Atherosclerosis is a complex multifocal arterial disease of
medium- and large-size arteries involving interactions of
multiple genetic and environmental factors. It is character-
ized by endothelial dysfunction, vascular inﬂammation, and
thebuildupoflipids, cholesterol,calcium,andcellulardebris
within the intima of the vessel wall [1]. This construction
results in plaque formation accumulating on the inner walls
of arteries, and as the artery walls thicken, the pathway for
blood narrows, and this can decrease or block blood ﬂow
diminishing oxygen supply to target organs. Atherosclerosis
represents a leading global cause of death and disability [2].
Although environmental factors such as diet or smoking
play an important role in atherosclerosis development,
genetic factors represent consequential determinant of ath-
erosclerotic cardiovascular disease risk. Advances in tech-
niques of molecular genetics have revealed that genetic dis-
orders signiﬁcantly inﬂuence susceptibility to atherosclerotic
vascular diseases. A large number of candidate genes, genetic
polymorphisms, and susceptibility loci associated with
atherosclerotic diseases have been identiﬁed in recent years
and, their number is rapidly increasing. Genetically con-
trolled arterial wall properties of carotid arteries inﬂuence
atherosclerosis susceptibility. The genetic risk of atheroscle-
rosis is conferred in part through known metabolic risk fac-
tors such as hypertension, dyslipidaemia, and diabetes melli-
tus, but together, the known risk features appear to be insuf-
ﬁcienttoexplainthehereditarypropensitytoatherosclerosis.
However, these risk factors alone do not account for the
entire contribution to risk of atherosclerotic disease. In
recent years, substantial interest in the identiﬁcation of addi-
tional genetic risk factors to atherosclerosis inevitably grows.
Several types of genetic investigations and approaches
have been conducted in the last years in order to prove
genetic impact of atherosclerotic process.
1.1. Monogenetic Heredity. Single-gene (mendelian) disor-
ders represent the most remarkable examples of the genetic
implication to atherosclerosis [3]. Several monogenic dis-
easeselevateplasmalevelsofLDLbyimpairingtheactivityof
hepatic LDL receptors, which normally clear LDL from the
plasma. Familial hypercholesterolemia was the ﬁrst mono-
genic disorder shown to cause elevated plasma cholesterol
levels. The primary defect in familial hypercholesterolemia
is a deﬁcit of LDL receptors, and more than 600 mutations
in the LDLR gene have been identiﬁed in patients with this
disorder [4]. The frequency of this genetic defect is 1 in2 Stroke Research and Treatment
1,000,000. Patients with heterozygous familial hypercholes-
terolemia have only 50% of the normal number of LDL
receptors in the liver. Heterozygous persons produce half the
normal number of LDL receptors, leading to an increase in
p l a s m aL D Ll e v e l sb yaf a c t o ro f2o r3 ,w h e r e a sL D Ll e v e l si n
those who are homozygous are 6 to 10 times normal levels.
Homozygous persons have severe coronary atherosclerosis
and usually die in childhood from myocardial infarction
[5]. Furthermore, deﬁciency of lipoprotein transport abol-
ishes transporter activity, resulting in elevated cholesterol
absorption and LDL synthesis. For example, mutations in
the APOB-100 gene, which encodes apolipoprotein B-100,
reduce the binding of apolipoprotein B-100 to LDL receptors
and slow the clearance of plasma LDL, causing a disorder
known as familial ligand-defective apolipoprotein B-100 [6].
Five diﬀerent mutations located in this region of the APOB
gene are reported to cause a high-cholesterol phenotype.
One in 1000 people is heterozygous for one of these
mutations. These patients are diagnosed as familial defective
APOB (FDB), which is clinically indistinguishable from
familial hypercholesterolemia [4, 7]. Mutations in PCSK9
have recently been shown to result in Mendelian forms of
increased LDL-C levels. PCSK9 encodes NARC-1 (neural
apoptosis regulated convertase), a newly identiﬁed human
subtilase that is highly expressed in the liver and contributes
to cholesterol homeostasis [8].
The various functions of ATP binding cassette trans-
porter 1 (ABCA1) became apparent after the discovery in
1999 that mutations in the ABCA1 gene caused Tangier dis-
ease (TD), an autosomal recessive hereditary disorder char-
acterized by severe HDL deﬁciency, sterol deposition in ma-
crophages and, premature atherosclerosis [9–11]. ABCA1
promotes cholesterol and phospholipid eﬄux from cells to
lipidpoor apolipoprotein (apoA1), the precursor of HDL,
and plays a major role in cholesterol homeostasis and reverse
cholesterol transport [12]. Sitosterolemia, a rare autosomal
disorder, results from loss-of-function mutations in genes
encoding two ABC transporters, ABCG5 and ABCG8, which
act in concert to export cholesterol into the intestinal lumen,
thereby diminishing cholesterol absorption [13, 14].
Very rare hereditary hypercholesterolemia with the prev-
alence <1 case per 10 million persons is autosomal recessive
hypercholesterolemia. The molecular cause is the presence of
defects in a putative hepatic adaptor protein, which then fails
to clear plasma LDL with LDL receptors [15]. Mutations in
the gene encoding that protein elevate plasma LDL to levels
similar to those seen in homozygous familial hypercholes-
terolemia [16].
1.2. Polygenetic Heredity. However, in the majority of cases it
is not possible to identify single-genetic determinants, and
it is likely that several major genes may contribute to
the manifestation of the disease. Most of our success
in understanding the genetic basis of common forms of
atherosclerosis has come from studies of candidate genes,
genes tested for their role in atherosclerosis in vitro, in vivo,
and in association studies [17]. Within the general pop-
ulation, polymorphisms within genes in lipid metabolism,
inﬂammation, and thrombogenesis are probably responsible
for the wide range of atherosclerotic diseases. A good
example of a candidate gene is apolipoprotein E (apoE). Yet
in the 1970s, Utermann et al. identiﬁed the common genetic
diﬀerences (polymorphisms) of apoE, and subsequent stud-
ies suggested associations with plasma cholesterol levels and
type III hyperlipidemia [18]. The apoE gene is located at
chromosome 19q13.2. Among the variants of this gene,
alleles E2, E3,a n dE4 constitute the common polymorphism
found in most populations. Of these variants, apoE3 is the
most frequent (>60%) in all populations studied [19]. The
role of apoE in plasma lipid metabolism has been studied
intensively[20,21].Thepolymorphismhasfunctionaleﬀects
on lipoprotein metabolism mediated through the hepatic
binding, uptake, and catabolism of chylomicrons, chylomi-
cron remnants, very low-density lipoprotein (VLDL), and
high-density lipoprotein subspecies [22]. Type III hyperlipi-
demia is an interesting example of a genetic interaction.
Almost all individuals with this uncommon hyperlipidemia
are homozygous for the E2 allele, but most individuals
who are homozygous for the E2 allele do not have the
disorder [23]. We can summarize from these observations
that other genetic or environmental interactions are required
to produce hyperlipidemia in addition to homozygosity for
the E2 allele. Another interesting example is CYBA gene
polymorphisms, including the C242T (rs4673) and the
−930A/G (rs9932581) which are implicated in the process
of atherosclerosis from a very early stage to the clinical
phase of cardiovascular diseases [24, 25]. The CYBA 242T
allele consistently shows a protective association against the
chronic inﬂammatory process presenting as impairment of
endothelial function and the development of coronary artery
disease [26]. In addition, the CYBA −930A/G gene polymor-
phismsmightmodifytheeﬀectofsmokingandhypertension
on early structural alterations on the arterial wall [27, 28].
An alternative genetic approach is conducting genome-
wide linkage studies to ﬁnd atherogenesis-regulating quanti-
tative trait loci (QTL). In addition, recently, the availability
of whole genome sequences in humans and mice, especially
the abundant SNP and haplotype information, has made
it possible to perform genomewide association studies in
order to identify responsible genes. Genomewide association
is thought to be more powerful than genomewide linkage
analysis to detect common alleles at a locus, but it is less
powerful if the extreme phenotypes of interest are due to the
segregation of many relatively rare alleles at that locus [29].
Recent experimental studies have revealed certain genetic
backgroundofLDLoxidationinthevesselwall,initiatingthe
formation of an early fatty streak lesion consisting mainly
of macrophages. Subsequently, a series of lipid-modifying
enzymes have been identiﬁed in the vessel wall, capable of
generating inﬂammatory mediators, which can further stim-
ulate plaque growth by enhancing cellular inﬂux [30]. One
of the lipid-modifying enzymes that have generated a lot of
interest recently is 5-lipoxygenase (5LO) which is produced
by macrophages and is an important enzyme in the conver-
sion of the lipid molecule arachidonic acid into leukotrienes.
Hence, 5LO may serve as a gene driving chronic inﬂamma-
tion and thereby the progression of atherosclerotic plaques.Stroke Research and Treatment 3
In line with this hypothesis, 5LO has recently been shown in
genetic and knockout studies in mouse to play a major role
in promoting plaque growth [31]. Based on these ﬁndings in
mice, polymorphisms in the promoter ofso 5LO have been
studied in patients and were correlated with the progression
of lesion formation based on measurements of the thickness
of the vessel wall [32]. These seminal observations place
genes interacting with 5LO in a prime position as candidate
genes for coronary artery disease (CAD). Among those genes
is ALOX5AP, encoding 5LO-activating protein (FLAP). A
recent study by Helgadottir et al. from deCODE genetics
elaborated successfully on this clinical question, by perform-
ing a linkage study in a large set of Icelandic families [33].
Sumof296familieswerestudied,including713patientswith
myocardial infarct, generating a highly susggestive linkage
peak to a locus on chromosome 13q.
Subsequently, this chromosomal region was further in-
vestigated by association analysis with 120 microsatellite
markers in a study including around 800 cases and controls.
This screen resulted in the detection of a haplotype spanning
two genes including ALOX5AP.The study by Dwyeret al. has
also investigated the role of gene-environment interactions
by studying the eﬀect of diet on 5LO promoter polymor-
phisms [32] .F i r s t ,as u b g r o u po fc a r r i e r so fap a r t i c u l a rp r o -
motervariantwasidentiﬁed,whichshowedincreasedcarotid
artery intima-media thickness. Second, it was shown in these
allele carriers that dietary arachidonic acid, the substrate for
5LO,increasedtheproductionofinﬂammatorymediators,as
compared to subjects that were fed a “marine” diet with N-3
fatty acids. Another gene identiﬁed in human linkage studies
of myocardial infarct, named, myocyte-enhancing factor 2A
(MEF2A), is expressed in endothelial cells of coronary arter-
ies. A 21-base pair deletion was identiﬁed in exon 11 in
all ten living members within the family, and not in family
members and an additional 119 individuals with normal
angiograms, strongly suggesting that the deletion is respon-
sible for myocardial infarct in this large family [34]. MEF2A
mutations may be a rare cause of myocardial infarct because
they are present in less than 2% of a US population of
207 patients [35]. Furthermore, adiponectin has thought
to have variety of metabolic eﬀects on obesity, insulin
sensitivity, and atherosclerosis. To identify genes inﬂuencing
variation in plasma adiponectin levels, Ling et al. performed
genomewide linkage and association scans of adiponectin in
two cohorts of subjects [36]. The genomewide linkage scan
was conducted in 789 family members of Turkish and south-
ern European and 2,280 northern and western European.
A whole genome association (WGA) analysis was carried
out on approximately 1,000 subjects with dyslipidemia and
1,000 overweight subjects with normal lipids. In conclusion,
these results support an eﬀect of DNA variation at the
ADIPOQ locus (the adiponectin structural gene) inﬂuencing
plasma adiponectin levels. However, the degree to which
DNA sequence variants at this locus inﬂuence health and
disease remains to be seen. Furthermore, these analyses in-
dicated that SNPs at the ADIPOQ locus were the most
strongly associated with adiponectin variation throughout
the entire genome.
2. Genetic Models for Atherosclerosis
The use of genetic models has greatly assisted investigations
of the natural history, mechanisms, and potential therapy
for atherosclerosis. In the past several years, the advent of
molecular techniques has enabled investigators to produce
additional novel genetic models of disease that have further
enhanced the study of vascular biology and medicine. Par-
ticularly valuable models in vascular diseases investigations
are inbred genetic strains, transgenic animals, gene targeting
by homologous recombination, and in vivo gene transfer
[37]. Distinct types of experimental design that has used
inbred mouse strains which diﬀer in their predisposition to
atherosclerosis has revealed more precise whether diﬀerences
in lipid proﬁles were restricted to particularly dietary terms
or reﬂect an underlying genetic factors that contribute to
atherosclerotic susceptibility. The most often used mouse
models of atherosclerosis were a high-fat model in which
inbred mice are fed a high-fat and cholesterol diet, ApoE-
deﬁcient mice fed either chow, a Western diet, and Ldlr-
deﬁcient mice fed either a Western diet or a high-fat and
cholesterol diet [38]. In order to exempt dyslipidemia as a
crucial factor for the development of atherosclerosis, one
of the ﬁrst investigators in this particular area, has used
apoE-deﬁcientmicestrains,extensivelystudiedmousemodel
of atherosclerosis that develops atherosclerosis on a chow
diet [39–41]. The authors bred apoE-deﬁcient mice that
had C57BL/6J or strain susceptible to atherosclerosis and
C3H/HeJ, a prototypical atherosclerosis mouse resistant
strain. The study demonstrated that in mice with an apoE-
deﬁcient background that were fed a chow diet, there were
not major diﬀerences in plasma lipids. Nevertheless, The
same study has revealed that mice with the C57BL/6J back-
ground developed markedly more atherosclerosis than mice
with C3H/HeJ background, indicating that diﬀerences in
atherosclerosis susceptibility do not reside in diﬀerences in
plasma lipid level. There are variety of cell types involved in
atherosclerotic process, including endothelial cells, smooth
muscle cells, monocytes, macrophages, and T lymphocytes.
Genetic variation that aﬀects some of these cell types could
inﬂuence susceptibility to atherosclerosis. In a second series
of experiments, Shi and collaborators have analyzed the
cellular compartments that have a role in genetic suscepti-
bility to atherosclerosis in mice [39]. They have generated
chimeric mice by performing bone marrow transplanta-
tion of C57BL/6J bone marrow into C3H/SW mice and
C3H/SWmarrowintoC57BL/6Jmice.Theyhaveprovedthat
C56BL/6J mice that received C3H/SW bone marrow were
not protected from atherosclerosis, and C3H/SW mice that
received C57BL/6J bone marrow did not develop increased
atherosclerosis. General conclusion of this study is that ath-
erosclerosis development was determined by the genotype of
the host rather than the genotype of bone marrow donor,
suggesting that genetic diﬀerences in atherosclerotic suscep-
tibility are not conditioned by the hematopoietic cells. Some
novelstudieshaveyieldedsimilarresults[42].Sequentiallyex
vivo studies of endothelial cells isolated from C57BL/6J mice
showed substantial induction of a limited panel of proin-
ﬂammatory genes (MCP-1, M-CSF, VCAM-1,a n dheme4 Stroke Research and Treatment
oxygenase-1) in response to minimally modiﬁed LDL (MM-
LDL), where endothelial cells from C3H/HeJ mice did not.
These results suggest the plausibility that the diﬀerences in
atherosclerotic susceptibility between these two mice strains
relate to genetic diﬀerence in the proinﬂammatory response
ofendothelialcellstoaspeciﬁcinﬂammatorystimulus,MM-
LDL.
3. Conclusions
Beyond the traditional risk factors, less well-established risk
factors for atherosclerosis development are being ﬁrmly
evaluated in recent years. The outcome of these eﬀorts will
notonlyunveilthemolecularbasisofatherosclerosisbutalso
allow prospective prediction from an early age of individuals
who are predisposed to develop premature atherosclerosis as
well as to facilitate the discovery of drug targets and individ-
ualized medications against the disease. Our understanding
of the pathogenesis of this process has evolved in the last few
decades, guiding our eﬀorts to ﬁnd treatments. The relatively
recent appreciation that inﬂammatory response plays a key
role in atherogenesis implies that inhibiting inﬂammation
may provide new anti-atherosclerosis therapy.
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